Safety and efficacy of obicetrapib in dyslipidemia: systematic review and meta-analysis

Back

ESC Professional Premium Access

Safety and efficacy of obicetrapib in dyslipidemia: systematic review and meta-analysis

Session: Novel insights into lipid-lowering pharmacotherapy

Topic: Lipid-Lowering Agents

Speaker: Mr A. Senk Juh (Logatec, SI)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Mr Amadej Senk Juh

Logatec (Slovenia)

1 follower

7 more presentations in this session

The differences in lipid lowering therapies and the LDL-C goal attainment in patients with ASCVD documented by cardiologists and general practitioners in Germany.

Speaker: Professor O. Weingaertner (Jena, DE)

Access

Abstract

Video

Icosapent ethyl reduces cardiovascular risk across apolipoprotein b and fasting triglyceride rich lipoprotein levels

Speaker: Doctor W. Malick (New York City, US)

Access

Abstract

Video

Inhibition of liver ApoC3 by GalNAc-conjugated siRNA RBD5044: first-in-human trial to evaluate the safety, pharmacokinetics (PK), and pharmacodynamic (PD) effects on atherogenic lipid profiles in heal

Speaker: Associate Professor A. Gabrielsen (Gothenburg, SE)

Access

Abstract

Video

Efficacy and safety of quadruple-drug fixed-dose single-pill combination therapy for hypertension and dyslipidemia: a prospective, multicenter, observational study

Speaker: Assistant Professor E. Park (Seoul, KR)

Access

Abstract

Video

Long-term survival of heFH or ACS patients on PCSK9 targeted therapy based on the real-life data from poland

Speaker: Professor M. Banach (Lodz, PL)

Access

Abstract

Video

Access the full session

Novel insights into lipid-lowering pharmacotherapy

Speakers: Mr A. Senk Juh, Professor O. Weingaertner, Doctor W. Malick, Associate Professor A. Gabrielsen, Assistant Professor E. Park...

Access

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources